NovoCure, Merck Team Up on Phase II Lung Cancer Trial

NovoCure announced today that it has entered a clinical trial collaboration agreement with Merck. Together, the companies will develop Tumor Treating Fields with Merck’s anti-PD-1 therapy, Keytruda for the treatment of non-small cell lung cancer (NSCLC).